Business Context and Reporting Period
Company: Clearmind Medicine Inc.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: December 2025 (Specifically December 3, 2025)
Context: The Company announced a registered direct offering of common shares to raise capital for general corporate purposes, including research and development and working capital.
Key Financial Metrics
Capital Raise Details:
- Shares Issued: 16,000,000 common shares
- Price Per Share: $0.10
- Aggregate Gross Proceeds: Approximately $1.6 million
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, operating cash flow, or margins.
- Debt/Liquidity: The filing text does not provide a clear value for existing debt levels or current liquidity positions, other than noting the use of existing cash alongside new proceeds.
Material Changes
This filing reports a material change in the Company's capital structure through the execution of a Securities Purchase Agreement. The Company is increasing its share count by 16,000,000 shares. No comparative financial data for prior periods is provided in this specific document to quantify changes in operational metrics.
Guidance, Outlook, and Risks
Use of Proceeds: Net proceeds will be used for general corporate purposes, including operating expenses, research and development (clinical and pre-clinical testing), working capital, future acquisitions, and capital expenditures.
Outlook: The Offering is expected to close on or about December 4, 2025.
Risks and Contingencies:
- The closing is subject to customary conditions; failure to satisfy these conditions may prevent the Offering from closing.
- Forward-looking statements regarding the closing date and use of funds are not guaranteed.
Investor Verification Checklist
- Verify the final closing date of the Offering (expected December 4, 2025) and confirm all closing conditions were met.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for specific terms, lock-up periods, or registration rights.
- Confirm the exact net proceeds after deducting underwriting discounts and offering expenses.
- Assess the dilution impact of the 16,000,000 new shares on existing shareholders.
- Monitor subsequent filings for updates on the specific allocation of funds to clinical trials versus general operating expenses.